The present retrospective study aims to evaluate the long-term effects of SGLT2 inhibitors versus allopurinol on sUA levels in patients with T2DM over a 36-month follow-up, with particular attention to changes in estimated glomerular filtration rate (eGFR) and major clinical outcomes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.